{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:55Z","timestamp":1786988995620,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020908","name":"Pfizer SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euo.2025.10.011","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:39:41Z","timestamp":1762951181000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications"],"prefix":"10.1016","volume":"9","author":[{"given":"St\u00e9phane","family":"Oudard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Campedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Serrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.10.011_b0005","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer today (version 1.1). Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today\/."},{"key":"10.1016\/j.euo.2025.10.011_b0010","article-title":"French AFU Cancer Committee Guidelines \u2013 Update 2024\u20132026: prostate cancer\u2014management of metastatic disease and castration resistance","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0015","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/ijms25031676","article-title":"New discoveries on protein recruitment and regulation during the early stages of the DNA damage response pathways","volume":"25","author":"Waters","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2025.10.011_b0020","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.3390\/ijms22105112","article-title":"PARP power: a structural perspective on PARP1, PARP2, and PARP3 in DNA damage repair and nucleosome remodelling","volume":"22","author":"van Beek","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2025.10.011_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","article-title":"PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistance","volume":"51","author":"Kanev","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0030","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.10.011_b0035","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2025.10.011_b0040","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2016.34.15_suppl.5010","volume":"34","author":"Hussain","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0045","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pros.23219","article-title":"A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling: clinical targeted NGS for prostate cancer","volume":"76","author":"Cheng","year":"2016","journal-title":"Prostate"},{"issue":"13 Suppl","key":"10.1016\/j.euo.2025.10.011_b0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1538-7445.AM2019-727","article-title":"Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies","volume":"79","author":"Green","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.10.011_b0055","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bulcan.2018.05.017","article-title":"D\u00e9faut de r\u00e9paration de l\u2019ADN: nouvelle piste th\u00e9rapeutique pour le cancer de prostate m\u00e9tastatique","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.euo.2025.10.011_b0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.10.011_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair\u2013deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0075","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP inhibitors and prostate cancer: to infinity and beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2025.10.011_b0080","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/JU.0000000000001570","article-title":"Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations","volume":"205","author":"Shore","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0090","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.euo.2025.10.011_b0100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0110","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2025.10.011_b0115","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.purol.2021.12.007","article-title":"Recherche d\u2019alt\u00e9rations des g\u00e8nes de r\u00e9paration de l\u2019ADN dans le cancer de la prostate: mise au point pratique du Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bulcan.2024.05.008","article-title":"Cancer de prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration et inhibiteurs de PARP : de la g\u00e9nomique tumorale aux nouvelles associations th\u00e9rapeutiques","volume":"112","author":"Oudard","year":"2025","journal-title":"Bull Cancer"},{"key":"10.1016\/j.euo.2025.10.011_b0130","first-page":"7427","article-title":"Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations","volume":"13","author":"McFarland","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.euo.2025.10.011_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.euo.2025.10.011_b0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/pcmedi\/pbaa030","article-title":"Recent advancements in PARP inhibitors-based targeted cancer therapy","volume":"3","author":"Zhou","year":"2020","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.euo.2025.10.011_b0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.10.011_b0150","doi-asserted-by":"crossref","first-page":"LBA16","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA16","article-title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.10.011_b0160","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/jcm11061734","article-title":"PARP inhibitors as monotherapy in daily practice for advanced prostate cancers","volume":"11","author":"Teyssonneau","year":"2022","journal-title":"J Clin Med"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.10.011_b0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2023.41.6_suppl.18","article-title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy","volume":"41","author":"Bryce","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0170","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2025.10.011_b0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.2025.43.5_suppl.155","article-title":"Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety","volume":"43","author":"Bryce","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.euo.2025.10.011_b0180","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.10.011_b0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0190","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.10.011_b0195","doi-asserted-by":"crossref","first-page":"LBA17","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA17","article-title":"TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0200","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.10.011_b0205","doi-asserted-by":"crossref","first-page":"S1326","DOI":"10.1016\/j.annonc.2023.10.087","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2025.10.011_b0210","first-page":"LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2025.10.011_b0215","volume":"43","author":"Fizazi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0220","unstructured":"European Medicines Agency. Talzenna (talazoparib). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf (accessed June 26, 2024)."},{"key":"10.1016\/j.euo.2025.10.011_b0225","unstructured":"European Medicines Agency. Lynparza (olaparib). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf."},{"key":"10.1016\/j.euo.2025.10.011_b0230","unstructured":"European Medicines Agency. Akeega (niraparib). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akeega-epar-product-information_en.pdf."},{"key":"10.1016\/j.euo.2025.10.011_b0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.011_b0240","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.euo.2025.10.011_b0245","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/aje\/kwaa190","article-title":"Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014\u20132018 French population study (the SPEAR cohort)","volume":"190","author":"Scailteux","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euo.2025.10.011_b0250","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2025.10.011_b0255","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2022.40.16_suppl.5018","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects","volume":"40","author":"Hussain","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0260","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer","author":"Cornford","year":"2025"},{"key":"10.1016\/j.euo.2025.10.011_b0265","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459."},{"key":"10.1016\/j.euo.2025.10.011_b0270","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.10.011_b0275","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2024.09.003","article-title":"Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer and BRCA1\/2 gene alterations: final analysis from the randomized phase 3 MAGNITUDE trial","volume":"88","author":"Rathkopf","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:57:19Z","timestamp":1775681839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2588931125002858"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.011","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}